Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Xalkori

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Pfizer agrees pricing and distribution deal with US government

    The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

    An estimated 2.4 million people globally are diagnosed with lung cancer each year

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

    Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

    Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

    - PMLiVE

    FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

    ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

    - PMLiVE

    MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

    Approximately 43,000 people are diagnosed with lung cancer every year in the UK

    2025 T40 open for submissions
    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links